Changing incidence of AIDS‐defining illnesses in the era of antiretroviral combination therapy

Objective:To determine the incidence of AIDS-defining opportunistic infections and malignancies over a 5-year period from 1992 to 1996. Study population:Subcohort of 1003 homosexual men with HIV infection and CD4 count less than 200 × 106cells/l from the Frankfurt AIDS Cohort Study. Methods:Data including the earliest date that a CD4 T-lymphocyte count < 200 × 106/l was reached and the dates of AIDS-defining events were compiled from medical records. Incidence analyses for AIDS-defining events and death during the subsequent 5 years (1992–1996) were performed using rates per 100 person-years of exposure. Results:During the observation period, the number of patients per year with CD4 T-lymphocyte counts < 200 × 106/l varied between 402 and 511. In 1992, 56.7% of patients experienced at least one AIDS-defining illness, and 20.7% in 1996. The annual number of AIDS-defining events per 100 patient-years of observation declined from 143.5 in 1992 to 38.3 in 1996, and the number of AIDS-related deaths fell from 25.7 to 12.9. Analysis of the number of events confirmed this trend for malignancies and single opportunistic infections, with the exception of mycobacterial diseases. Conclusions:The incidence of AIDS-defining events in patients with advanced HIV infection at Frankfurt University Hospital has declined by more than 70% from 1992 to 1996.

[1]  M A Fischl,et al.  The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. , 1987, The New England journal of medicine.

[2]  Revision of the CDC surveillance case definition for acquired immunodeficiency syndrome. Council of State and Territorial Epidemiologists; AIDS Program, Center for Infectious Diseases. , 1987, MMWR supplements.

[3]  J. Kahn,et al.  AIDS-associated non-Hodgkin's lymphoma in San Francisco. , 1989, JAMA.

[4]  Incidence of Kaposi's sarcoma in a cohort of homosexual men infected with the human immunodeficiency virus type 1. The Multicenter AIDS Cohort Study Group. , 1990, Journal of acquired immune deficiency syndromes.

[5]  S. Steinberg,et al.  Development of non-Hodgkin lymphoma in a cohort of patients with severe human immunodeficiency virus (HIV) infection on long-term antiretroviral therapy. , 1990, Annals of internal medicine.

[6]  G. Rutherford,et al.  Kaposi's sarcoma among homosexual and bisexual men enrolled in the San Francisco City Clinic Cohort Study. , 1990, Journal of Acquired Immune Deficiency Syndromes.

[7]  J. Phair,et al.  Effect of zidovudine and Pneumocystis carinii pneumonia prophylaxis on progression of HIV-1 infection to AIDS , 1991, The Lancet.

[8]  B. Saltzman,et al.  Survival differences in patients with AIDS. , 1991, Journal of acquired immune deficiency syndromes.

[9]  Opportunistic non-Hodgkin's lymphomas among severely immunocompromised HIV-infected patients surviving for prolonged periods on antiretroviral therapy--United States. , 1991, MMWR. Morbidity and mortality weekly report.

[10]  J. Carlin,et al.  Predictive value of CD4 lymphocyte numbers for the development of opportunistic infections and malignancies in HIV-infected persons. , 1991, Journal of acquired immune deficiency syndromes.

[11]  S. Broder,et al.  The occurrence of opportunistic non-Hodgkin's lymphomas in the setting of infection with the human immunodeficiency virus. , 1991, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  T Creagh-Kirk,et al.  Natural history of advanced HIV disease in patients treated with zidovudine. The Zidovudine Epidemiology Study Group. , 1992, AIDS.

[13]  M. Lederman,et al.  Incidence of lymphomas and other cancers in HIV-infected and HIV-uninfected patients with hemophilia. , 1992, JAMA.

[14]  O. Hamouda,et al.  Changes in the Spectrum of AIDS‐Defining Conditions and Decrease in CD4+ Lymphocyte Counts at AIDS Manifestation in Germany from 1986 to 1991 , 1992, AIDS.

[15]  P M Southern,et al.  Incidence of Mycobacterium avium-intracellulare complex bacteremia in human immunodeficiency virus-positive patients. , 1992, The Journal of infectious diseases.

[16]  J. Phair,et al.  Clinical manifestations of AIDS in the era of pneumocystis prophylaxis. Multicenter AIDS Cohort Study. , 1993, The New England journal of medicine.

[17]  Factors associated with Kaposi's sarcoma in a cohort of homosexual and bisexual men. , 1993, Journal of acquired immune deficiency syndromes.

[18]  J. Chmiel,et al.  Composite risk score for Kaposi's sarcoma based on a case-control and longitudinal study in the Multicenter AIDS Cohort Study (MACS) population. , 1993, American journal of epidemiology.

[19]  C. Rabkin Epidemiology of AIDS‐related malignancies , 1994, Current opinion in oncology.

[20]  J. Phair,et al.  Incidence of clinical AIDS conditions in a cohort of homosexual men with CD4+ cell counts < 100/mm3. Multicenter AIDS Cohort Study. , 1994, The Journal of infectious diseases.

[21]  M. Moroni,et al.  Prevention of symptomatic recurrences of esophageal candidiasis in AIDS patients after the first episode: a prospective open study. , 1994, The American journal of gastroenterology.

[22]  S. Buchbinder,et al.  Temporal trends of opportunistic infections and malignancies in homosexual men with AIDS. , 1994, The Journal of infectious diseases.

[23]  C. Katlama,et al.  HIV‐related non‐Hodgkin's lymphoma among European AIDS patients , 1995, European journal of haematology.

[24]  B. Nathwani,et al.  Role of zidovudine antiretroviral therapy in the pathogenesis of acquired immunodeficiency syndrome-related lymphoma. , 1995, Blood.

[25]  Long-term survival without clinical AIDS after CD4+ cell counts fall below 200 x 10(6)/l. , 1995, AIDS.

[26]  J. Neaton,et al.  Frequencies of opportunistic diseases prior to death among HIV‐infected persons , 1995, AIDS.

[27]  J. Phair,et al.  Long-term survival without clinical AIDS after CD4+ cell counts fall below 200 x 10(6)/l. , 1995, AIDS.

[28]  D. Hoover The effects of long term zidovudine therapy and Pneumocystis carinii prophylaxis on HIV disease. A review of the literature. , 1995, Drugs.

[29]  J. Nielsen,et al.  Randomized study of sulfamethoxazole-trimethoprim versus aerosolized pentamidine for secondary prophylaxis of Pneumocystis carinii pneumonia in patients with AIDS. , 1995, Scandinavian journal of infectious diseases.

[30]  P. Rosenberg,et al.  Changing patterns of Kaposi's sarcoma in Danish acquired immunodeficiency syndrome patients with complete follow-up. The Danish Study Group for HIV Infection (DASHI). , 1995, American journal of epidemiology.

[31]  A. Tosteson,et al.  The international epidemiology of disseminated Mycobacterium avium complex infection in AIDS , 1996, AIDS.

[32]  S. Hammer,et al.  The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. AIDS Clinical Trials Group Study 175 Virology Study Team. , 1996, The New England journal of medicine.

[33]  J. Meynard,et al.  Detection of human herpesvirus 8 DNA sequences before the appearance of Kaposi's sarcoma in human immunodeficiency virus (HIV)-positive subjects with a known date of HIV seroconversion. , 1996, The Journal of infectious diseases.

[34]  J. Ward,et al.  Toxoplasmic encephalitis in HIV-infected persons: risk factors and trends , 1996, AIDS.

[35]  J. Darbyshire,et al.  Delta: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals , 1996, The Lancet.

[36]  S. Mallal,et al.  Declining incidence and later occurrence of Kaposi's sarcoma among persons with AIDS in Australia: the Australian AIDS cohort , 1996, AIDS.

[37]  S. Hammer,et al.  A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study Team. , 1996, The New England journal of medicine.

[38]  V. Johnson,et al.  Correspondence between the effect of zidovudine plus lamivudine on plasma HIV level/CD4 lymphocyte count and the incidence of clinical disease in infected individuals , 1997, AIDS.

[39]  P. Kvale,et al.  Incidence of Tuberculosis in the United States among HIV-Infected Persons , 1997, Annals of Internal Medicine.

[40]  Impact of disseminated Mycobacterium avium-complex infection on survival of HIV-infected patients. , 1997, European journal of medical research.

[41]  C. Katlama,et al.  Reductions in HIV‐1 disease progression for zidovudine/lamivudine relative to control treatments: a meta‐analysis of controlled trials , 1997, AIDS.